Dermata Therapeutics, INC DEF 14A proxy statements

Dermata Therapeutics has issued its 2026 proxy statement seeking stockholder approval for director elections, auditor ratification, warrant issuances, and an equity plan amendment.

Dermata Therapeutics, Inc. has officially filed a Definitive Additional Materials proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission.

Dermata Therapeutics, Inc. is calling an Annual Meeting of Stockholders to address critical Nasdaq listing compliance issues, including a proposed reverse stock split and the ratification of recent dilutive warrant issuances that raised over $8 million.

Dermata Therapeutics is holding its annual meeting of stockholders on May 7, 2024, to vote on key proposals including a reverse stock split, an amendment to the equity incentive plan, and the ratification of its independent auditor.

Dermata Therapeutics is asking stockholders to approve an amendment to its equity incentive plan and a reverse stock split at its upcoming annual meeting on May 7, 2024.